A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
Key Details
- 1AI tool SÉMIL uses pathology slide images and written descriptions to stratify relapse risk for stage II bowel cancer patients.
- 2Validated on over 1220 patients across three independent cohorts and multiple Australian institutions.
- 3Greatest predictive accuracy when AI assessments align with pathologist evaluations.
- 4Can be integrated into existing clinical digital pathology workflows, supporting but not replacing human clinicians.
- 5Findings published in Gastroenterology (July 2026) with no conflicts of interest reported.
- 6Research involved collaboration among several top Australian institutions and cancer centers.
Why It Matters
Accurate risk stratification can ensure high-risk stage II bowel cancer patients receive timely, potentially life-saving therapy, while sparing low-risk patients from unnecessary treatment. The study demonstrates how AI can augment pathology workflows for more consistent, data-driven clinical decisions in oncology.
Source
EurekAlert
Related News
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.
•EurekAlert
AI-Enhanced Imaging Breaks Barriers in Complex Media for Biomedical Use
Researchers developed a physics-based machine learning imaging system that enhances visibility through complex media, holding promise for biomedical imaging.